Pfizer recalls migraine drug for possible microbial contamination

Pfizer has recalled two lots of migraine drug Relpax after finding those lots “may not meet Pfizer’s in-house microbiological specification for the potential presence” of two kinds of bacteria.

Sanofi wins appeal for Jevtana patent

A federal appeals court affirmed the validity of Sanofi's first patent on prostate-cancer drug, Jevtana.

Pharma in review: trending stories 8/16/19

Most popular Pharma Manufacturing stories from the past seven days.

Top Novartis scientists exited company ahead of data scandal

More details are emerging about the months leading up to Novartis’s admission that data results for its gene therapy Zolgensma were manipulated.

Ovarian cancer drug hits main goal in new study

An AstraZeneca treatment scored an important victory in the quest to offer new treatments for ovarian cancer.

Eli Lilly psoriasis drug bests J&J rival

The drugmaker's Taltz beat out Johnson & Johnson's Tremfya at achieving total skin clearance after 12 weeks of treatment

FDA expands Regeneron's Eylea approval

The blockbuster eye med is now indicated for an Injection prefilled syringe, which will provide physicians with a new way to administer the treatment with fewer preparation steps

Regeneron drug boosts survival of Ebola to 90 percent

A new study has shown that a pair of experimental treatments could dramatically increase the chances of surviving Ebola.

Amgen wins Enbrel patent protections — for now

Amgen has fought off a patent challenge from Novartis to its blockbuster anti-inflammatory, Enbrel.

GSK announces leadership changes

GlaxoSmithKline announced that Jack Bailey, President U.S. Pharmaceuticals, has decided to step down from his role at the end of the year.

Natco Pharma API plant hit with Form 483

Natco Pharma has received a Form 483 with six observations from the U.S. FDA for the drugmaker's active pharmaceutical ingredient facility located outside Hyderabad, India.

Bayer pays $600M for stem cell therapy developer

Bayer has acquired BlueRock Therapeutics in a deal valued at $600 million that will give the drugmaker a platform to research and develop new stem cell therapies.

Synthorx founder mysteriously leaves Scripps Research

A lead scientist at La Jolla’s Scripps Research has left the biomedical institute

Pharma Manufacturing announces the 2019 Pharma Innovation Award winners

After several acquisitions, Cambrex is now on track to be bought

One of the industry’s leading small-molecule CDMOs is being acquired for $2.4 billion.

Teva’s CFO resigns in the midst of ongoing financial woes

Teva Pharmaceuticals announced this week that its chief financial officer is stepping down.

FDA says Novartis gene therapy drug application contains manipulated data

On May 24, the FDA approved Zolgensma, a gene therapy product intended to treat children less than two years of age with spinal muscular atrophy, but was informed recently by the product’s manufacturer about a data manipulation issue

GSK drops Ebola vaccine development

The vaccine candidates will be transferred to the Sabin Vaccine Institute in Washington with no financial element in the deal

Novo Nordisk buys Purdue Pharma plant

In an attempt to streamline its supply chain of diabetes drugs in the U.S., Novo Nordisk has scooped up a plant from Purdue Pharma.

Roche’s Tecentriq clears new hurdle in bladder cancer

Roche’s Tecentriq is showing new promise as an early treatment for bladder cancer.